EXAS.Exact Sciences CORP

10-Q: Exact Sciences Reports Q1 2025 Results: Revenue Up 11% Driven by Screening and Precision Oncology Growth

Sentiment:

Quarterly Report

📋All filings for Exact Sciences CORP
🔒Login to Follow

Exact Sciences Corporation announces an 11% increase in revenue for the first quarter of 2025, driven by growth in both screening and precision oncology segments.

Better than expectedThe company's revenue increased by 11% year-over-year.The company's net loss improved compared to the same period last year.The company's cash provided by operating activities improved significantly.

Summary

  • Exact Sciences Corporation reported an 11% increase in revenue for Q1 2025, reaching $706.785 million compared to $637.524 million in Q1 2024.
  • Screening revenue increased by 13.7% to $540.007 million, driven by Cologuard test volume growth.
  • Precision Oncology revenue increased by 2.5% to $166.778 million, primarily due to increased Oncotype DX breast cancer tests.
  • The company launched Cologuard Plus and Oncodetect in Q1 2025.
  • Net loss for the quarter was $(101.215) million, an improvement from $(110.228) million in the same period last year.
  • Cash provided by operating activities was $30.8 million, a significant improvement of $113.1 million compared to the prior year.
  • The company had $347.127 million in cash and cash equivalents and $439.048 million in marketable securities as of March 31, 2025.
  • The company expects to launch Cancerguard EX, an LDT version of the multi-cancer early detection test, in the second half of 2025.
  • The company's top priorities for 2025 are to champion customers and team, elevate the product portfolio, and amplify impact.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and improved cash flow. However, the continued net losses and uncertainties regarding future regulations temper the overall sentiment.

Positives

  • Revenue increased by 11% year-over-year, indicating strong business growth.
  • Screening revenue showed significant growth (13.7%), driven by Cologuard test volume.
  • Net loss improved compared to the same period last year, suggesting improved operational efficiency.
  • Cash provided by operating activities increased significantly, indicating better cash management.
  • The launch of Cologuard Plus and Oncodetect expands the company's product portfolio.
  • The company is focused on improving patient adherence to screening, which could drive future growth.
  • The company was recognized as a Gallup Exceptional Workplace for the second year in a row.

Negatives

  • The company continues to incur net losses, with an accumulated deficit of approximately $4.60 billion.
  • Precision Oncology revenue growth was relatively modest at 2.5%.
  • The company acknowledges uncertainty regarding the future regulation of LDTs, which could impact its business.

Risks

  • The company's ability to achieve and sustain profitability is uncertain.
  • Future regulation of LDTs could materially impact the development and commercialization of tests.
  • Macroeconomic conditions such as inflation and exchange rate fluctuations could impact future operating results.
  • The company relies on certain suppliers, and any disruption could affect its operations.
  • The company faces competition for its products and services.
  • The company's success depends on obtaining and maintaining regulatory approvals and complying with applicable regulations.
  • The company's success depends on protecting and enforcing its intellectual property.

Future Outlook

The company expects continuing revenue growth for its Cologuard and Oncotype tests, subject to seasonal variability, timing of care gap programs, and additional growth from recent and upcoming product launches. The company also expects to launch Cancerguard TM EX in the second half of 2025.

Management Comments

  • During the first quarter of 2025, we achieved many critical milestones, including: delivering tests results to 1.2 million people including a record number for Oncotype DX, growing total revenue 11% year-over-year while improving gross margin and decreasing operating expenses as a percentage of revenue, generating cash provided by operating activities of $30.8 million for the three months ended March 31, 2025, an improvement of $113.1 million in comparison to the three months ended March 31, 2024, launching Cologuard Plus TM , our next-generation Cologuard test, and Oncodetect TM , our molecular residual disease (MRD) test, and being recognized as a Gallup Exceptional Workplace for the second year in a row.
  • Our top priorities for 2025 are to (1) champion our customers and team, (2) elevate our product portfolio, and (3) amplify our impact.

Industry Context

Exact Sciences operates in the cancer screening and diagnostics market, which is characterized by increasing awareness of early detection benefits and technological advancements in testing methodologies. The company's focus on non-invasive screening and precision oncology aligns with current trends in personalized medicine and patient-centric healthcare.

Comparison to Industry Standards

  • Exact Sciences competes with companies like Guardant Health, Foundation Medicine (Roche), and Myriad Genetics in the cancer diagnostics space.
  • Cologuard's non-invasive stool-based DNA test competes with traditional colonoscopy and other stool-based tests like FIT (fecal immunochemical test).
  • The reported 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity for Cologuard Plus is a key metric to compare against competitors' screening tests.
  • Oncotype DX's ability to predict chemotherapy benefit and cancer recurrence is a key differentiator compared to other genomic tests for breast cancer.
  • The company's investment in multi-cancer early detection (MCED) tests like Cancerguard puts it in competition with companies like Grail (Illumina) and Freenome, which are also developing blood-based multi-cancer screening tests.

Legal Proceedings

  • The Company filed suit against Geneoscopy, Inc. (Geneoscopy) in the United States District Court for the District of Delaware, alleging that certain of Geneoscopy's products infringe the 781 Patent and seeking unspecified monetary damages and injunctive relief (the 781 Action) and in January 2024, the Company amended the complaint, alleging that Geneoscopy has made false and misleading statements in the marketing and promotion of its product, in violation of the Lanham Act.
  • In May 2024, the Company filed a second complaint against Geneoscopy alleging infringement of the Company's U.S. Patent No. 11,970,746 (the 746 Patent), which has been consolidated with the 781 Action.
  • Geneoscopy filed counterclaims against the Company challenging the validity of the patents at issue and alleging breach of contract, misappropriation of trade secrets, unfair competition, and other violations of state and federal law seeking unspecified monetary damages and injunctive relief.
  • On July 16, 2024, the Company filed a motion for preliminary injunction seeking an order prohibiting Geneoscopy from selling its infringing Colosense test in the United States, which the Court has taken under advisement.
  • Geneoscopy has petitioned the United States Patent and Trademark Office to institute an inter partes review (IPR) challenging the validity of the 781 Patent and the 746 Patent before the Patent Trial and Appeals Board (PTAB).
  • The PTAB has instituted review for both patents and the Company intends to defend the validity of both patents.
  • A final decision of the review of the 781 Patent will be made on or before July 26, 2025 and a final decision of the review of the 746 Patent will be made on or before February 14, 2026.
  • On February 20, 2025, Geneoscopy filed a motion to stay the district court litigation pending IPR of the 781 and 746 Patents, which is fully briefed and pending before the Court.

Stakeholder Impact

  • Shareholders: The report provides information on the company's financial performance and strategic initiatives, which can inform investment decisions.
  • Employees: The company's recognition as a Gallup Exceptional Workplace and its focus on championing its team can positively impact employee morale and retention.
  • Patients: The launch of new screening and diagnostic tests can improve access to early cancer detection and personalized treatment options.
  • Healthcare Providers: The company's products and services provide valuable tools for cancer screening, diagnosis, and treatment planning.
  • Suppliers: The company's reliance on certain suppliers highlights the importance of maintaining strong relationships to ensure a stable supply chain.

Next Steps

  • Increase adoption of current tests.
  • Launch Cologuard Plus, Oncodetect, and Cancerguard tests.
  • Invest in clinical trials to enhance existing products and bring new diagnostics to patients and providers.
  • Improve patient adherence to screen more people.
  • Recruit patients for the FDA registrational Study of All comeRs (SOAR) trial.

Key Dates

DateDescription
February 1995Exact Sciences Corporation was incorporated.
June 2009The Company entered into an exclusive, worldwide license agreement with the Mayo Foundation for Medical Education and Research (Mayo).
August 2014Cologuard test received FDA approval.
November 5, 2021Previous revolving loan agreement date.
August 2, 2022The Company completed the sale of the intellectual property and know-how related to the Company's Oncotype DX Genomic Prostate Score test (GPS test).
June 2023The Company entered into an exclusive license agreement with Broad Institute, Inc. (Broad Institute) to utilize the Minor Allele Enriched Sequencing Through Recognition Oligonucleotides (MAESTRO) technology in the Company's MRD testing.
July 2023The Company entered into a co-exclusive development and license agreement with Watchmaker Genomics, Inc. (Watchmaker) under which the Company granted Watchmaker a co-exclusive license to the non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications (TAPS).
October 2023The FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SECs Disclosure Update and Simplification Initiative.
November 2023The Company filed suit against Geneoscopy, Inc. (Geneoscopy) in the United States District Court for the District of Delaware, alleging that certain of Geneoscopy's products infringe the 781 Patent and seeking unspecified monetary damages and injunctive relief (the 781 Action).
December 2023The FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.
March 2024Results from the pivotal BLUE-C study published in the New England Journal of Medicine in March 2024 showed 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity when age-weighted to the U.S. population with no findings on colonoscopy.
April 2024The Company entered into a privately negotiated exchange and purchase agreement with certain holders of the Company's convertible notes due in 2028 (2028 Notes).
May 1, 2024The Company entered into termination agreements (the Termination Agreements) with TGen for the purpose of terminating the license and sponsored research agreement relating to the TARDIS technology and an additional sponsored research agreement with a broader scope (collectively, the Original Agreements).
May 2024The Company filed a second complaint against Geneoscopy alleging infringement of the Company's U.S. Patent No. 11,970,746 (the 746 Patent), which has been consolidated with the 781 Action.
May 2024The FDA issued a final rule (the LDT Rule), which amended the FDA's regulations to make explicit that LDTs are devices under the FDCA.
July 1, 2024The Company entered into an agreement with TwinStrand Biosciences, Inc. (TwinStrand), under which TwinStrand licensed to the Company intellectual property related to the error correction technology in next-generation sequencing.
July 16, 2024The Company filed a motion for preliminary injunction seeking an order prohibiting Geneoscopy from selling its infringing Colosense test in the United States, which the Court has taken under advisement.
July 2024Our Cancerguard test was approved as an Investigational Device Exemption by the FDA to be used within a real-world evidence study, providing an opportunity to test 25,000 people over the next three years.
August 2024The first patient was enrolled within this study at Baylor Scott & White, the primary study site.
September 2024The Companys license agreement with Mayo was most recently amended and restated in September 2020.
September 2024The company presented performance data for its blood-based colorectal cancer screening test at the ESMO Congress, showing sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at specificity of 90% for negative samples confirmed by colonoscopy.
October 2024The FDA approved our Cologuard Plus test for adults ages 45 and older of average risk for colorectal cancer.
November 2024The FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.
November 2024Results from a multi-center, prospective, case-control ASCEND-2 study showed 60% overall sensitivity at 98.5% specificity when excluding cancer organ types with average-risk standard of care screening, and 67% overall sensitivity for the six most aggressive cancer organ types with the shortest 5-year survival rate.
January 2025Complete findings from Alpha-CORRECT were published in the Journal of Surgical Oncology.
January 13, 2025The Company entered into a senior secured revolving credit agreement (the Revolving Credit Agreement) with a syndicate of lenders.
January 15, 2025Upon maturity of the 2025 Notes on January 15, 2025, the Company made a cash payment of $250.4 million in settlement of the total principal of the 2025 Notes and accrued interest that was previously outstanding as of December 31, 2024.
February 20, 2025Geneoscopy filed a motion to stay the district court litigation pending IPR of the 781 and 746 Patents, which is fully briefed and pending before the Court.
March 2025Cologuard Plus test was launched in late March 2025.
March 31, 2025The U.S. District Court in the Eastern District of Texas vacated the LDT rule, holding that LDTs are not subject to FDA regulation as devices under the FDCA.
April 2025Our Oncodetect test was launched as a laboratory developed test (LDT) in April 2025.
April 2025The Company received the cash payment of $28.0 million related to the 2024 earnout year, which was included in prepaid expenses and other current assets as of March 31, 2025.
April 2025In April 2025, the Company made a payment of $20.0 million in settlement of the development milestone related to the Company's acquisition of Ashion, which was accrued as of March 31, 2025.
Mid-2025BLUE-C pivotal study results for our blood-based colorectal cancer screening test are expected in mid-2025 and performance degradation is expected for advanced precancerous lesion sensitivity and overall CRC sensitivity.
Second Quarter 2025Based on results from the aforementioned studies, we expect to obtain Medicare reimbursement through the Molecular Diagnostic Services Program (MolDX) in the second quarter of 2025.
Second Half 2025We expect to launch Cancerguard TM EX, an LDT version of this test, in the second half of 2025.
July 26, 2025A final decision of the review of the 781 Patent will be made on or before July 26, 2025.
February 14, 2026A final decision of the review of the 746 Patent will be made on or before February 14, 2026.
2030 to 2031The projected fiscal year of payment range associated with the regulatory and development milestones related to the Company's acquisition of Thrive is from 2030 to 2031.
2039The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued).

Keywords

Exact Sciences, Cologuard, Oncotype DX, Screening, Precision Oncology, Revenue, Net Loss, Q1 2025, Molecular Residual Disease, MRD, Cancerguard, Colorectal Cancer, Diagnostic Tests

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.